Alligator Bioscience AB (OSTO:ATORX) Notes Receivable: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ATORX Alligator Bioscience AB OSTO:ATORX
39 GF Score
Price kr0.17
GF Value kr0.01
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Notes Receivable?

Alligator Bioscience AB OSTO:ATORX -3.60% 39 Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:ATORX with a GF Score™ of 39/100 and a GF Value™ of kr0.01 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Alligator Bioscience AB's Notes Receivable for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Alligator Bioscience AB Notes Receivable Related Terms

Alligator Bioscience AB Notes Receivable Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB Notes Receivable Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alligator Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ATORX
39GF Score
Alligator Bioscience AB OSTO:ATORX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of kr0.00 Mil mean?
Alligator Bioscience AB (OSTO:ATORX) has a Notes Receivable of kr0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Alligator Bioscience AB and its competitors.
Is Alligator Bioscience AB's Notes Receivable too high?
Alligator Bioscience AB's current Notes Receivable is kr0.00 Mil. Overall, Alligator Bioscience AB has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's Notes Receivable compare to VRTX and REGN?
Alligator Bioscience AB's Notes Receivable of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current Notes Receivable is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (OSTO:ATORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.17 — trading 1612% above its estimated fair value. The current Notes Receivable is kr0.00 Mil. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Alligator Bioscience AB (OSTO:ATORX), the current Notes Receivable is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alligator Bioscience AB (OSTO:ATORX) Overvalued in 2026?

Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued. The current stock price of kr0.17 is trading 1612% above its estimated GF Value™ of kr0.01. GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:ATORX:

  • Notes Receivable: kr0.00 Mil
  • GF Value™: kr0.01 vs. price of kr0.17 (1612% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the OSTO:ATORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alligator Bioscience AB Business Description

Other Exchanges 0RK9:UK7AL0:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score

Get the complete analysis for OSTO:ATORX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.17
Price
kr0.01
GF Value